Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Pre-Budget Report response - GSK comments on patent box
GSK welcomes the introduction of a new measure announced in the Pre-Budget Report to stimulate future investment in the UK.
-
GSK initiates second pivotal Phase III trial for investigational cardiovascular medication Darapladib
GSK today announced initiation of the second large-scale Phase III clinical trial to evaluate long-term treatment.
-
GSK Update: GSK’s Arepanrix™ H1N1 pandemic vaccine prequalified by the World Health Organization
First prequalification for an H1N1 pandemic vaccine
-
GSK completes extension of strategic collaboration with Aspen
GSK announced that yesterday it completed the extension of its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen)
-
GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed
GSK becomes Laboratory Services Provider
-
Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan
GlaxoSmithKline (GSK) announced today that it has filed its vaccine for the prevention of rotavirus gastroenteritis.
-
GlaxoSmithKline and Gilead announce agreement to commercialise Viread® for chronic hepatitis B in key Asian countries
GlaxoSmithKline (GSK) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement to commercialise.
-
GSK Regulatory Update: Avodart
GSK expects to resubmit the file shortly. This action is not the result of new findings related to safety or efficacy.
-
Pandemic 2009 Influenza Update: Pandemrix™ data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline (GSK) today announced that over 40 million doses of its adjuvanted pandemic H1N1 vaccine have been distributed to countries.
-
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction
GSK and Nabi announced an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine.
-
Pandemic 2009 Influenza Update: US FDA approves GSK’s pandemic H1N1 vaccine
GSK today announced that FDA has approved a sBLA for its unadjuvanted influenza A (H1N1) pandemic vaccine.
-
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries
GSK today announced that it has signed an agreement with WHO to donate 50 million doses of its influenza vaccine.
-
Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)
The trial involves 168 adults aged over 60 years of age, and was designed to evaluate the tolerability and immunogenicity.
-
GlaxoSmithKline and XenoPort announce extension of GSK1838262 (XP13512) FDA review date to 9 February 2010
GSK and XNPT today announced that FDA has extended the original PDUFA goal date for its review of NDA for GSK to February 9, 2010.
-
World Health Organization Grants Prequalification for Global Use to GSK’s 10-Valent Synflorix™ Vaccine
First prequalification for pneumococcal disease vaccine, a threatening disease affecting many children; follows first World Pneumonia Day.
-
World’s largest malaria vaccine trial now underway in seven African countries
Pivotal testing of RTS,S is on track for target enrollment of 16,000 children
-
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
CEO promises 'relentless pursuit' of new treatments
-
Retigabine Regulatory Update
on 30 October, they filed a New Drug Application with the FDA and MAA with EMEA for retigabine.
-
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
Benlysta 10 mg/kg plus standard of care met its primary efficacy endpoint by achieving a statistically significant improvement.
-
Results announcement for the third quarter 2009
See the quarterly results page for more information.